+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020

  • ID: 4911679
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 107 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Cancer Advances Inc
  • Cinclus Pharma AG
  • CJ HealthCare Corp
  • Eisai Co Ltd
  • RaQualia Pharma Inc
  • Renexxion LLC
  • MORE
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 7, 7, 3 and 4 respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Cancer Advances Inc
  • Cinclus Pharma AG
  • CJ HealthCare Corp
  • Eisai Co Ltd
  • RaQualia Pharma Inc
  • Renexxion LLC
  • MORE
  • Introduction
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ahn-Gook Pharmaceutical Co Ltd
  • CalyGene Biotechnology Inc
  • Cancer Advances Inc
  • Changchun Serene Pharmaceutical Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Cinclus Pharma AG
  • CJ HealthCare Corp
  • Daewoong Pharmaceutical Co Ltd
  • Eisai Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Hunan Mingrui Pharmaceutical Co Ltd
  • Ilyang Pharmaceutical Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Renexxion LLC
  • Sam-A Pharm Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Takeda Pharmaceutical Co Ltd
  • Trio Medicines Ltd
  • XuanZhu Pharma Co Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll